A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
a study on Lung Cancer Non-Small Cell Lung Cancer Stomach Cancer Gastroesophageal Junction Cancer Hodgkin's Lymphoma Lymphoma Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma T Cell Lymphoma Melanoma Skin Cancer/Melanoma Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Bladder Cancer Ovarian Cancer Breast Cancer Cervical Cancer
Non-small Cell Lung Cancer Gastric Carcinoma Gastroesophageal Junction Carcinoma Classical Hodgkin Lymphoma Diffuse Large B-cell Lymphoma Peripheral T-cell Lymphoma Cutaneous Melanoma Head and Neck Squamous Cell Carcinoma Bladder Cancer Ovarian Cancer Triple Negative Breast Cancer Cervical Cancer NSCLC cHL HNSCC TNBC DLBCL PTCL-NOS Seattle Genetics Lymphoma Carcinoma Lymphoma, Large B-Cell, Diffuse Triple Negative Breast Neoplasms Squamous Cell Carcinoma of Head and Neck Lymphoma, T-Cell, Peripheral Stomach Neoplasms SEA-TGT sasanlimab
Lead Scientist at University of California Health
- Bridget Keenan, MD (ucsf)
I am a physician scientist who works in translational cancer research and medical oncology. My clinical practice is in the Cancer Immunotherapy Clinic, where I work with patients with solid organ cancers who are being treated on early phase immunotherapy trials. I also attend on the Oncology Consult inpatient service.
- accepting new patients
- Start Date
- Completion Date
- Seagen Inc.
- Phase 1 research study
- Study Type
- Expecting 397 study participants
- Last Updated